NanoViricides, Inc. (NASDAQ:NNVC) | Finanzwire

Basculer en Français

9784	Companies
195997	Keywords
127055	Articles
104233	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 01/29/2024 at 12:30, 2 years ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV

NV-387 NanoViricides Inc NV-CoV-2 Phase 1a/1b Clinical Trial Antiviral Therapy
PRESS RELEASE

published on 01/04/2024 at 12:30, 2 years ago

NanoViricides to Present at the Biotech Showcase in San Fransisco
NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections.

NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE

published on 11/28/2023 at 12:40, 2 years 2 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE

published on 11/15/2023 at 12:45, 2 years 2 months ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE

published on 11/14/2023 at 12:45, 2 years 2 months ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE

published on 10/16/2023 at 12:45, 2 years 3 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE

published on 10/12/2023 at 12:45, 2 years 3 months ago

NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE

published on 08/21/2023 at 12:45, 2 years 5 months ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE

published on 07/11/2023 at 12:45, 2 years 6 months ago

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE

published on 07/06/2023 at 12:45, 2 years 6 months ago

Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs

Accesswire

Published on 02/02/2026 at 15:00, 6 hours 29 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform
Published on 02/02/2026 at 14:30, 6 hours 59 minutes ago

Unusual Machines Promotes Drew Camden to President
Published on 02/02/2026 at 14:30, 6 hours 59 minutes ago

Predictiv AI Provides Pilot Update from Innovate Calgary's Soaring Higher Challenge with Calgary Airports and WestJet
Published on 02/02/2026 at 14:30, 6 hours 59 minutes ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
Published on 02/02/2026 at 14:00, 7 hours 29 minutes ago

Paymetrex Launches Patent Licensing Program to Monetize Mobile Payments IP Portfolio

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 1 hour 29 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 1 hour 32 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 1 hour 47 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 2 hours 24 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 18:59, 2 hours 30 minutes ago

EQS-Adhoc: Deutsche Rohstoff AG: Oil and Gas Reserves increase by 46% – NPV of USD 542 million at USD 60 WTI oil price

Les Echos

Published on 02/02/2026 at 18:23, 3 hours 6 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:00, 3 hours 29 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 17:35, 3 hours 54 minutes ago

Disclosure of transactions in own shares from January 26 to January 30, 2026
Published on 02/02/2026 at 17:22, 4 hours 7 minutes ago

Statement of transactions in own shares from January 26, 2026 to January 30, 2026
Published on 02/02/2026 at 08:45, 12 hours 44 minutes ago

BAIKOWSKI: Business growth in 2025

View all LES ECHOS COMFI WIRE